Enveric Biosciences (ENVB) Minority Interest (2016 - 2023)
Enveric Biosciences (ENVB) posted Minority Interest of $1.1 million for Q2 2023, up 4.33% sequentially from $1.0 million in Q1 2023, and up 64.94% YoY from $637840.0 in Q2 2022.
Enveric Biosciences (ENVB) Minority Interest (2016 - 2023) Analysis & Trends
Enveric Biosciences has reported Minority Interest for 4 years, with the latest figure at $1.1 million in Q2 2023.
- Quarterly Minority Interest rose 64.94% year-over-year to $1.1 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $1.1 million (up 64.94% YoY) and the FY2022 annual result came in at $885028.0, changed N/A from the prior year.
- Minority Interest rose to $1.1 million in Q2 2023 per ENVB's latest filing, from $1.0 million in the prior quarter.
- Over five years, Minority Interest peaked at $1.1 million in Q2 2023 and troughed at $637840.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 1.05 Mn |
| Mar 31, 2023 | 1.01 Mn |
| Dec 31, 2022 | 885,028.00 |
| Sep 30, 2022 | 761,434.00 |
| Jun 30, 2022 | 637,840.00 |
| Sep 30, 2017 | 18,504.00 |
| Jun 30, 2017 | 11,872.00 |
| Mar 31, 2017 | -3,516.00 |
| Dec 31, 2016 | 3,382.00 |